Hotstocked Newsletters

Promoted Companies

PROMOTION HISTORY
SORT BY:

Oncolytics Biotech Inc. (ONCY)

Total paid for Promotions this month: $0
E-mails this Month: 1
Estimated Volume Generated: $0
Research Report on ONCY: Click to see
* The information presented is based on information for Jul , 2015
  Wall Street Mover July 6, 20159:30 am ESTSymbol: ONCY Last Closing Price: $.53Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers.  The Company was formed to explore the oncolytic capability of the retrovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most ...read more
Promoter: Wall Street Mover Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY No compensation UNKNOWN
Max Profit: 5.14 % Gain at close: -8.00 %
  Is this email not displaying correctly? View it in your browser. Take Advantage. Oncolytics Biotech, Inc. ONCY ONCY emerged from our extended watchlist and stole the show yesterday with an exceptional intraday run. The stock saw an early morning low of .80 then proceeded to bull its way upward for the remainder of the session, ...read more
Promoter: Blue Horseshoe Stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY Unknown compensation UNKNOWN
Max Profit: 12.90 % Gain at close: -6.45 %
  Is this email not displaying correctly? View it in your browser. Take Advantage. Oncolytics, BioTech, Inc. ONCY Jumping off of yesterday's extended watchlist was ONCY, which not only produced a fruitful session yesterday, but continued to push its upper limits this morning as it touched a premarket high of .90. After tagging ...read more
Promoter: Blue Horseshoe Stocks Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY Unknown compensation UNKNOWN
Max Profit: 1.19 % Gain at close: -10.73 %
Positive Data from Brain Cancer Study (Must Read!)     Oncolytics Biotech Inc. (ONCY)   ONCY reported that an abstract detailing early data from translational study looking at the intravenous administration of its REOLYSIN(R) to patients with primary or metastatic brain tumors will be presented at the at the American Society of Clinical Oncology Annual Meeting being held May 30 – June 3, 2014 in Chicago, Illinois.   Based ...read more
Promoter: Crwefinance.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY Unknown compensation UNKNOWN
Max Profit: 1.35 % Gain at close: -10.81 %
Positive Top-Line Data from Study of Its Lead Product in Head and Neck Cancers (Must Read!!!!) (Mailing list information, including unsubscription instructions, is located at the end of this message.) Oncolytics Biotech Inc. (ONCY)   Keep a close eye on ONCY. The company reported before the opening bell positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN(R) in combination with carboplatin ...read more
Promoter: Crwefinance.com Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -4.84 %
Monday Hot News Alert On... Must Read (Mailing list information, including unsubscription instructions, is located at the end of this message.) Oncolytics Biotech Inc. (Nasdaq:ONCY)   Keep a close eye on ONCY. The company reported before the market opens a poster presentation containing updated efficacy data from a Phase 2 study examining the use of its proprietary formulation of the human reovirus REOLYSIN(R), in combination with carboplatin ...read more
Promoter: penny to buck Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
ONCY Unknown compensation UNKNOWN
Max Profit: 0.00 % Gain at close: -4.84 %
Video not found or You must install the Flash Plugin for your Browser in order to view this movie